daxdilimab
mAbexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Apr 27, 2022 (NCT05368103)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
ILT7
Leukocyte immunoglobulin-like receptor subfamily A member 4 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4594330 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05669014 | Phase 2 | Dec 31, 2022 | Horizon Therapeutics, LLC |
| NCT05540665 | Phase 2 | Nov 30, 2022 | Horizon Therapeutics, LLC |
| NCT05591222 | Phase 2 | Oct 12, 2022 | Horizon Therapeutics, LLC |
| NCT05430854 | Phase 2 | Jun 1, 2022 | Horizon Therapeutics, LLC |
| NCT05368103 | Phase 2 | Apr 27, 2022 | Horizon Therapeutics, LLC |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Horizon Therapeutics, LLC | For profit | 5 | 5 | 1 | 2022 |
1 organizations
Page 1 / 1